Statins Overcome Resistance to Tyrosine Kinase Inhibitors in Patient-Derived, Oncogene-Driven NSCLC Models

被引：0
|
作者：
Ma, W. [1 ]
Tian, E. [1 ]
Li, Q. [2 ]
Wei, S. [1 ]
Zhou, C. [3 ]
Yoneda, K. [4 ]
Li, T. [1 ]
机构：
[1] Univ Calif Davis, Ctr Comprehens Canc, Internal Med, Div Hematol Oncol, Sacramento, CA 95817 USA
[2] Univ Calif Davis, Ctr Comprehens Canc, Canc Ctr, Sacramento, CA 95817 USA
[3] Univ Calif Davis, Dept Pathol, Pathol, Sacramento, CA 95817 USA
[4] Univ Calif Davis, Ctr Comprehens Canc, Div Pulm, Internal Med, Sacramento, CA 95817 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
statin; oncogene-driven non-small cell lung cancer; resistance;
D O I：
10.1016/j.jtho.2019.08.1211
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.14-60
引用
收藏
页码：S579 / S579
页数：1
相关论文
共 50 条
  • [1] Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
    Ma, Weijie
    Wei, Sixi
    Li, Qianping
    Zeng, Jie
    Xiao, Wenwu
    Zhou, Chihong
    Yoneda, Ken Y.
    Zeki, Amir A.
    Li, Tianhong
    [J]. MOLECULAR CANCER THERAPEUTICS, 2024, 23 (05) : 700 - 710
  • [2] TYROSINE KINASE INHIBITORS AS A TREATMENT OF SYMPTOMATIC CNS METASTASES IN ONCOGENE-DRIVEN NSCLC
    Benouaich-Amiel, Alexandra
    Gal, Omer
    Dudnik, Elizabeth
    Rotem, Ofer
    Finket, Inbar
    Peretz, Idit
    Zer, Alona
    Mandel, Jacob
    Siegal, Tali
    Bar, Jair
    Yust-Katz, Shlomit
    [J]. NEURO-ONCOLOGY, 2020, 22 : 1 - 1
  • [3] Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC
    Gal, Omer
    Dudnik, Elizabeth
    Rotem, Ofer
    Finkel, Inbar
    Peretz, Idit
    Zer, Alona
    Mandel, Jacob
    Amiel, Alexandra
    Siegal, Tali
    Bar, Jair
    Lobachov, Anastasiya
    Yust, Shlomit
    [J]. JOURNAL OF ONCOLOGY, 2020, 2020
  • [4] Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap
    Gandara, David R.
    Lara, Primo N., Jr.
    Mack, Philip C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (26) : 2839 - +
  • [5] Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC
    Ma, Weijie
    Zeng, Jie
    Chen, Shuai
    Lyu, Yue
    Toomey, Kyra A.
    Phan, Chinh T.
    Yoneda, Ken Y.
    Li, Tianhong
    [J]. BIOMARKER RESEARCH, 2021, 9 (01)
  • [6] Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC
    Weijie Ma
    Jie Zeng
    Shuai Chen
    Yue Lyu
    Kyra A. Toomey
    Chinh T. Phan
    Ken Y. Yoneda
    Tianhong Li
    [J]. Biomarker Research, 9
  • [7] The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC
    Patil, Tejas
    Staley, Alyse
    Nie, Yunan
    Sakamoto, Mandy
    Stalker, Margaret
    Jurica, James M.
    Koehler, Kenna
    Cass, Amanda
    Kuykendall, Halle
    Schmitt, Emily
    Filar, Emma
    Reventaite, Evelina
    Davies, Kurt D.
    Nijmeh, Hala
    Haag, Mary
    Yoder, Benjamin A.
    Bunn, Paul A.
    Schenk, Erin L.
    Aisner, Dara L.
    Iams, Wade T.
    Marmarelis, Melina E.
    Camidge, D. Ross
    [J]. JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (02):
  • [8] Overcoming MET-mediated resistance in oncogene-driven NSCLC
    Reischmann, Nadine
    Schmelas, Carolin
    Molina-Vila, Miguel Angel
    Jordana-Ariza, Nuria
    Kuntze, Daniel
    Garcia-Roman, Silvia
    Simard, Manon A.
    Musch, Doreen
    Esdar, Christina
    Albers, Joachim
    Karachaliou, Niki
    [J]. ISCIENCE, 2023, 26 (07)
  • [9] Are Immune Checkpoint Inhibitors Effective Against Uncommon Oncogene-Driven NSCLC Subtypes?
    Eguren-Santamaria, Inaki
    Sanmamed, Miguel F.
    Gil-Bazo, Ignacio
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (04) : 489 - 492
  • [10] Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer
    Campo, Meghan
    Al-Halabi, Hani
    Khandekar, Melin
    Shaw, Alice T.
    Sequist, Lecia V.
    Willers, Henning
    [J]. ONCOLOGIST, 2016, 21 (08): : 964 - 973
12345